Multimedia
.jpg?impolicy=website&width=360&height=270 "How to build a unicorn in 6 years")
-
Is Sputnik V the shot in the arm India needs?
As India's inoculation drive slows down, Russia's Sputnik V is the third vaccine in the country's kitty. With the necessary approvals in place, at least six manufacturers in India, including the Hetero Group of Companies, will be making a total of 900 million doses of the contentious vaccine. Divya Shekhar and Manu Balachandran give you a peek into the big gambit to ramp up production of the Sputnik V in India
-
A snapshot of the 12th Anniversary Special
For Forbes India's 12th anniversary, the team came up with 12 pertinent topics or sectors and challenges that India faces today, and invited experts like CEOs, investors, entrepreneurs, economists, philanthropers, to write about their vision for the future of that idea. The topics range from mobility to healthcare, food to luxury, entertainment and sports, jobs and inequality, philanthropy, and more. Ruchika Shah gives you a peek into the Anniversary special issue with a quick snapshot of the wealth of essays you'll find in it
-
Mumbai graffiti captures the mood of Maximum City
Graffiti is a medium of cultural reflection of the society, often depicting the city's most pertinent emotions. Mumbai's walls have recently filled up with graffiti and murals about Covid-19; Deepak Turbhekar captures them and the emotions of the people of Maximum City
-
Covid-19 Vaccine FAQs: We answer your frequently asked questions about coronavirus vaccines
As the next phase of vaccine drive began for 18-45 age group recently, there are still doubts about the vaccine. In part two of our Vaccine FAQs series, Dr Jeenam Shah, a consultant pulmonologist with Saifee, Wockhardt and Bhatia Hospitals in Mumbai who has been treating Covid-19 patients since March last year, answers the most frequently asked questions—from 'how effective will the vaccine be on the ones who had contracted the virus in second wave' to 'should one wait for Pfizer of J&J vaccine'?
-
Vaccine FAQs: Have questions before you get Covid-19 vaccine?
Before India's drive to vaccinate everyone between 18 to 45 years begins effectively, we understand that you may have a lot of questions. In part one of our Vaccine FAQs series, Dr Malcolm D Pestonji, M.S.(Ortho) (Bom) D. Ortho, Golden Park Hospital, who has worked with Covid-19 patients since the first wave
-
AU Small Finance's Sanjay Agarwal shows financial inclusion can be a viable business
Sanjay Agarwal built AU Small Finance Bank into a $4.4 billion giant by taking banking to the hinterland. Forbes India's Samar Srivastava gives you a peek into the latest Forbes India cover story
-
A year after: A nation altered by the viral second wave
India has the highest seven-day Covid-19 case trajectory seen in any country and the grim distinction of most single-day infections in any country ever since the beginning of the coronavirus pandemic. With a dearth of key drugs, beds and the return of restrictions across major cities, the nation is coping with its own contradictions.
-
Inside our latest edtech issue
Sequoia Capital bet big on education technology—ed tech—with over a dozen investments, including in industry giants Byju's and Unacademy. Forbes India' Rajiv Singh unpacks the cover story of the fortnight
-
Inside our 2021 investment special issue
A peek into our 2021 Investment Special where we dissect and analyse the parameters that will shape investment strategies for the new financial year. Forbes India's Salil Panchal and Samar Srivastava take you through what you can expect in the new issue which is on stands now
-
I want to give kids a choice through education, something I lacked in my own life: Andre Agassi
Tennis-legend-turned-education philanthropist on why he is investing big on early-stage learning
-
Pandemic forces a phygital, seasonless outing for FDCI X Lakme Fashion Week: 10 things to know
From a drive-in show to a virtual one, here are some of the ways in which the pandemic made its presence felt at the FDCI X Lakme Fashion Week